July 16, 2026 |
Following ASCO® 2026, Inizio’s experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year’s congress revealed for pharmaceutical organisations. Together, they examine the evolving role of congresses, from experience design and technology to strategy, measurement and commercial impact.

Simon Davenport, Global Head of Environments at Inizio Engage, explores the characteristics that set the most successful congress experiences apart. Drawing on observations from the exhibition floor, the article highlights three key principles: creating a clear and consistent scientific narrative, designing interactions that genuinely enhance engagement rather than relying on technology for its own sake, and building flexible experiences that allow HCPs to engage at different levels. The article explains why thoughtful experience design is becoming increasingly important as congress environments grow more competitive.
Read full article here.
Nick Bellomo, VP of Experience and Technology at Inizio Medical, examines the technology and engagement innovations that stood out across ASCO® 2026. From immersive LED environments and AI-powered interactions to tactile, low-tech activations, the article explores how organisations are rethinking the use of technology to create more meaningful scientific engagement. It concludes that the most effective congress experiences combine creativity with purposeful design to strengthen scientific communication and generate valuable behavioural insights.
Read full article here.
Lynsey Holbrook, Global Client Development Director at Inizio Engage, focuses on the growing complexity of congress planning and the challenge of demonstrating return on investment. The article explores why many pharmaceutical organisations struggle to connect strategy, execution and measurement, despite increasing investment in congresses. It outlines how a more connected approach can help teams align stakeholders, create more coordinated delegate experiences and measure the activities that drive meaningful scientific and commercial outcomes.
Read full article here.
This content was provided by Inizio
Latest Content from Inizio
Commercial pharma launches depend on confident, evidence-led decisions. Yet many launch teams are still working with fragmented data spread across multiple systems, making it difficult to understand market readiness, prioritize…
Following ASCO® 2026, Inizio’s experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year’s congress revealed for pharmaceutical organisations. Together, they…
Key insights from ASCO® 2026, including oncology trends, scientific highlights, and strategies for smarter congress engagement.
Across sessions, panels, and conversations on the ground in Denver, there was a noticeable shift in both mindset and momentum. Many of the themes discussed in previous years are now…
Inizio, the global commercialization partner to the health and life sciences industry, today announced the launch of Intelligent Congress – a connected, end-to-end solution designed to help pharma organizations maximize…
Integrated capabilities combining advanced analytics, pharmacy, and specialized talent to improve access, affordability, and adherence
Pharma USA is North America’s largest cross-functional pharma event and Inizio was there to offer insights on patient engagement, accelerated product launches, and Intelligent Commercialization™. Now we’re back in the…
Discover how AI, analytics and real-world data are reshaping Medical Affairs.
Discover how teams from across Inizio provided a range of integrated services to give a client’s product the best chance of launch success.
Explore Inizio Medical’s key takeaway from ISMPP EU 2026, including AI governance, transparency, patient partnership and evolving impact measurement.
